Home /Research /Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial

OTHER

Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial

Yifan Chang, Xianzhi Zhao, Yu‐Tian Xiao, Shi Yan, Weidong Xu, Ye Wang, Huojun Zhang, Shancheng Ren

Year: 2022
Citations: 8

Keywords

MedicineProstate cancerProstatectomyRadiation therapyAndrogen deprivation therapyGrading (engineering)Neoadjuvant therapyProstateClinical endpointCancer

Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial

Keywords

Related papers

Statistical Learning Theory

Fractional Differential Equations

Applied Nonlinear Control

Genetic Programming: On the Programming of Computers by Means of Natural Selection